Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk's new CEO, Mike Doustdar, is considering layoffs as part of cost-saving measures. He aims to review all company expenses, including salaries, but assures a fair process. Doustdar, a ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Danish leader will face a challenging landscape among competitors ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...